Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Volcano Adds CardioSpectra High-Res Imaging To Intravascular Portfolio

This article was originally published in The Gray Sheet

Executive Summary

Intravascular imaging firm Volcano hopes to have an application before FDA for optical coherence tomography sometime next year after inking a deal worth up to $63 million to acquire the technology developer CardioSpectra

You may also be interested in...



Volcano Adds ‘Forward-Looking’ IVUS To Interventional Imaging Suite

Volcano expects to add Novelis' forward-looking intravascular ultrasound (FLIVUS) to the tools available with its s5i intravascular imaging system by the end of 2009

Volcano Adds ‘Forward-Looking’ IVUS To Interventional Imaging Suite

Volcano expects to add Novelis' forward-looking intravascular ultrasound (FLIVUS) to the tools available with its s5i intravascular imaging system by the end of 2009

InfraReDx Launches LipiScan To Evaluate Coronary Plaque

InfraReDx is launching its catheter-based LipiScan coronary imaging system, which relies upon near-infrared spectroscopy to identify plaque most likely to cause heart attacks and death, following April 25 FDA 510(k) clearance of the device

Related Content

UsernamePublicRestriction

Register

MT025605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel